Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.67
+1.1%
$3.09
$2.46
$4.15
$320.07M0.25323,610 shs286,948 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$33.90
-1.3%
$33.28
$29.31
$61.38
$4.14B0.591.52 million shs1.30 million shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.74
+0.0%
$0.70
$0.53
$7.11
$123.95M0.32.57 million shs1.03 million shs
Morphic Holding, Inc. stock logo
MORF
Morphic
$56.99
$56.76
$19.34
$57.00
$2.85B1.491.27 million shs400 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.71
$6.65
$381.02M0.93.64 million shsN/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+6.38%+15.05%+31.54%+11.89%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%+2.23%+5.67%-9.26%-37.68%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
0.00%+1.25%+29.60%-44.78%-87.89%
Morphic Holding, Inc. stock logo
MORF
Morphic
0.00%0.00%0.00%0.00%+79.04%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+36.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.3589 of 5 stars
3.32.00.00.00.62.51.3
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.9281 of 5 stars
4.52.00.04.60.00.80.0
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
4.5853 of 5 stars
4.15.00.03.40.00.81.9
Morphic Holding, Inc. stock logo
MORF
Morphic
1.0241 of 5 stars
1.00.00.04.80.03.30.0
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.7618 of 5 stars
3.10.00.04.70.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0063.49% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.92109.21% Upside
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.13
Hold$4.78546.40% Upside
Morphic Holding, Inc. stock logo
MORF
Morphic
2.00
Hold$57.000.02% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside

Current Analyst Ratings Breakdown

Latest RVNC, MORF, AVIR, CYTK, and IRWD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $80.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/24/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$55.00
4/16/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$5.20 per shareN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M219.20N/AN/A($1.15) per share-29.48
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$317.68M0.38$0.05 per share15.49($1.88) per share-0.39
Morphic Holding, Inc. stock logo
MORF
Morphic
$520K5,490.11N/AN/A$12.31 per share4.63
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$880K-$0.20N/A2.96N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)
Morphic Holding, Inc. stock logo
MORF
Morphic
-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)

Latest RVNC, MORF, AVIR, CYTK, and IRWD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.56-$0.40+$0.16-$0.40N/AN/A
5/7/2025Q1 2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.94
19.94
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
3.34
3.34
Morphic Holding, Inc. stock logo
MORF
Morphic
N/A
24.13
24.13
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
Morphic Holding, Inc. stock logo
MORF
Morphic
94.25%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
12.70%
Morphic Holding, Inc. stock logo
MORF
Morphic
25.60%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7085.58 million70.09 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million116.20 millionOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
220161.82 million141.27 millionOptionable
Morphic Holding, Inc. stock logo
MORF
Morphic
10050.09 million37.27 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable

Recent News About These Companies

Crown Laboratories Now Operates Under the Name Revance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.67 +0.04 (+1.10%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$3.65 -0.02 (-0.54%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$33.90 -0.46 (-1.34%)
Closing price 07/3/2025 02:25 PM Eastern
Extended Trading
$34.52 +0.62 (+1.81%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.74 +0.00 (+0.04%)
As of 07/3/2025 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Morphic stock logo

Morphic NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)
As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.